Skip to main content
Log in

Abstract

Since many drug-drug pharmacokinetic interactions are dependent on the concentrations of the interacting species, the degree of interaction should be a graded phenomenon varying with drug and/or metabolite concentration and thus drug administration and time. Hence one should be able to develop predictive kinetic models for such interactions. A change in drug plasma levels when a compound is administered as a single dose together with another drug can arise from a change drug clearance, displacement from binding sites, a change in elimination rates, or a combination of any or all of these possibilities. The interaction of phenobarbital and the sparingly soluble oral antifungal agent, griseofulvin, is one example. Analysis shows that there is no change in elimination half- life of griseofulvin but that phenobarbital reduces the extent of griseofulvin absorption rather than enhances its elimination. Sulfaphenazole inhibits the metabolism and markedly prolongs tolbutamide plasma levels. An anticipated sudden drop in the excretion rate of the tolbutamide metabolites at maximum sulfonamide plasma levels is associated with an almost complete block of tolbutamide oxidation. The inhibitor constant K1 for this interaction has been calculated, allowing one to predict tolbutamide and metabolite levels when the inhibitor is administered. Drug- drug interaction resulting from protein displacement has been hypothesized by a number of authors. However, the potentiation of the anticoagulant warfarin in patients receiving phenylbutazone is more complicated than has been envisioned previously. While displacement occurs, data suggest that phenylbutazone primarily acts through selective inhibition to alter the isomeric composition and potency of the racemic warfarin administered. The warfarin- phenylbutazone interaction study stresses the importance of measuring metabolites as well as intact drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. L. F. Prescott. Pharmacokinetic drug interactions.Lancet (N. Am. Ed.) 11: 1239–1243 (1969).

    Article  Google Scholar 

  2. H. F. Morelli. Drug interactions. InClinical Pharmacology (K. H. Melmon and H. F. Morrelli, eds.), MacMillan Press, Washington, 1970, Chap. 17, pp. 585–604.

    Google Scholar 

  3. R. A. Branch, D. G. Shand, C. R. Wilkinson, and A. S. Nies. The deduction of lidocaine clearance byd l propranolol-An example of hemodynamic drug interaction.J. Pharmacol. Exptl. Therap. 184: 515–519 (1973).

    CAS  Google Scholar 

  4. A. G. MacGregor. Symposium 7. Clinical effects of interaction between drugs.Proc. Royal Soc. Med. 58: 943–946 (1965).

    CAS  Google Scholar 

  5. K. Melmon, H. F. Morelli, J. A. Oates, A. H. Conney, T. N. Tozer, B. P. Harpole, and T. H. Clark. Drug interactions that affect your patient.Patient Care 1: 32–71 (1967).

    Google Scholar 

  6. E. A. Hartshorn. Drug interaction.Drug Intelligence 2: 174–180 (1968).

    Google Scholar 

  7. D. L. Azarnoff and A. Hurwitz. Drug interactions.Pharmacology for Physicians 4: No. 2 (1970).

    Google Scholar 

  8. P. D. Hansten.Drug Interactions, 2nd ed., Lea & Febiger, Philadelphia, 1973.

    Google Scholar 

  9. E. W. Martin.Hazards of Medication. J. B. Lippincott, Philadelphia, 1971.

    Google Scholar 

  10. J. G. Wagner. Pharmacokinetics.Ann. Rev. Pharmacol. 8: 67–93 (1968).

    Article  CAS  PubMed  Google Scholar 

  11. G. Levy. Kinetics of pharmacologic effects.Clin. Pharmacol. Therap. 7: 362–372 (1966).

    CAS  Google Scholar 

  12. G. Levy and M. Gibaldi. Pharmacokinetics of drug action.Ann. Rev. Pharmacol. 12: 85–97 (1972).

    Article  CAS  PubMed  Google Scholar 

  13. G. Levy and C. Regardh. Drug biotransformation interactions in man. V. Acetaminophen and salicylic acid.J. Pharm. Sci. 60: 608–611 (1971).

    Article  CAS  PubMed  Google Scholar 

  14. G. Levy and H. Yamada. Drug biotransformation interactions in man. III. Acetaminophen and salicylamide.J. Pharm. Sci. 60: 215–221 (1971).

    Article  CAS  PubMed  Google Scholar 

  15. E. M. Sellers and J. Koch-Weser. Kinetic and clinical importance of displacement of warfarin from albumin by acidic drugs.Ann. N. Y. Acad. Sci. 179: 213–225 (1971).

    Article  CAS  PubMed  Google Scholar 

  16. D. Bushfield, K. J. Child, and R. M. Atkinson. An effect of phenobarbitone on blood levels of griseofulvin in man.Lancet 2: 1042–1043 (1963).

    Article  Google Scholar 

  17. S. Riegelman, M. Rowland, and W. L. Epstein. Griseofulvin-phenobarbital interaction in man.JAMA 213: 426–431 (1970).

    Article  CAS  PubMed  Google Scholar 

  18. P. M. Aggeler and R. A. O'Reilly. Effect of heptabarbital on the response to bishydroxy-coumarin in man.J. Lab. Clin. Med. 74: 229–238 (1970).

    Google Scholar 

  19. L. K. Christensen. Drug induced changes of the blood glucose lowering effect of oral hypoglycemic agents. InPharmacology and Mode of Oral Hypoglycemic Agents, Vol. VI (A. Loubatieres and A. E. Rengold, eds.), Casa Editrice “Il Ponte,” Milano, 1969, pp. 116–136.

    Google Scholar 

  20. D. A. Hussar. The hypoglycemic agents-Their interactions.J. Am. Pharm. Ass. NS 10: 619–624 (1970).

    CAS  Google Scholar 

  21. R. C. Thomas and C. J. Ikeda. The metabolic fate of tolbutamide in man and in the rat.J. Med. Chem. 9: 507–512 (1966).

    Article  CAS  PubMed  Google Scholar 

  22. E. Schulz and F. H. Schmidt. Abbanhemmung von Tolbutamide durch Sulfaphenazol beim Menschen.Pharmacol. Clin. 2: 150–152 (1970).

    Article  CAS  Google Scholar 

  23. L. K. Christensen, J. M. Hansen, and M. Kristensen. Sulfaphenazole induced hypoglycemic attacks in tolbutamide treated diabetes.Lancet 2: 1298–1301 (1963).

    Article  CAS  PubMed  Google Scholar 

  24. W. Riess, K. Schmid, and H. Keberle. Über den Stoffwechsel von Sulfaphenazol.Klin. Wschr. 43: 740–744 (1965).

    Article  CAS  PubMed  Google Scholar 

  25. S. B. Matin, J. Karam, and M. Rowland. Kinetics of drug-drug interaction: Tolbutamide-sulfaphenazole interaction in man.J. Pharmacokin. Biopharm. (submitted).

  26. J. R. Gillette. Techniques for studying drug metabolismin vitro. InFundamentals of Drug Metabolism (B. N. La Du, H. G. Mandel, and E. L. Way, eds.), Williams and Wilkins, Baltimore, 1971, Chap. 19, pp. 400–418.

    Google Scholar 

  27. L. J. P. Duncan and J. D. Baird. Oral insulin substitutes.Scot. Med. J. 2: 171–182 (1957).

    CAS  PubMed  Google Scholar 

  28. M. Rowland. Drug administrations and regimens. InClinical Pharmacology (K. H. Melmon and H. F. Morrelli, eds.), MacMillan Press, New York, 1972, Chap. 2, pp. 21–60.

    Google Scholar 

  29. J. G. Wagner, J. I. Northam, C. D. Alway, and O. S. Carpenter. Blood levels of drug at the equilibrium state after multiple dosing.Nature 207: 1301–1302 (1965).

    Article  CAS  PubMed  Google Scholar 

  30. U. C. Dubach, A. Burke, and J. Raaflaub. Einfluss von Sulfonamiden auf die blutzucker-senkende Wirkung oral Antidiabetika.Schweiz. Med. Wschr. 96: 1483–1486 (1966).

    CAS  Google Scholar 

  31. E. G. McQueen and W. M. Wardell. Drug displacement from protein binding; Isolation of a redistributional drug interactionin vivo.Brit. J. Pharmacol. 43: 312–324 (1971).

    CAS  Google Scholar 

  32. M. Rowland, P. Thomson, K. H. Melmon, and A. Guichard. The disposition kinetics of lidocaine in man.Ann. N. Y. Acad. Sci. 179: 383–398 (1971).

    Article  CAS  PubMed  Google Scholar 

  33. P. M. Aggeler, R. A. O'Reilly, L. Leong, and P. Kowitz. Potentiation of anticoagulant effect of warfarin by phenylbutazone.New Engl. J. Med. 276: 496–501 (1967).

    Article  CAS  PubMed  Google Scholar 

  34. H. M. Solomon and J. J. Schrogie. The effect of various drugs on the binding of warfarin-14C to human albumin.Biochem. Pharmacol. 16: 1219–1226 (1967).

    Article  CAS  PubMed  Google Scholar 

  35. R. J. Lewis, W. F. Trager, K. K. Chan, A. Breckenridge, and M. Orme. Stereochemical considerations of the metabolism of warfarin in man. Studies with the R and S isomer.J. Clin. Invest. (in press).

Download references

Author information

Authors and Affiliations

Authors

Additional information

Much of the work reported in this paper was supported by a grant from the National Institutes of Health, Bethesda, Maryland, NIGMS 16496.

This paper was presented by Dr. Rowland at the Conference on Pharmacology and Pharma-cokinetics; Problems and Perspectives, October 30–November 1, 1972, at the Fogarty International Center, National Institutes of Health, Bethesda, Maryland. This paper, in a slightly different format, will be published in the Proceedings of the Conference by Plenum Press, New York.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rowland, M., Matin, S.B. Kinetics of drug-drug interactions. Journal of Pharmacokinetics and Biopharmaceutics 1, 553–567 (1973). https://doi.org/10.1007/BF01059791

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01059791

Key words

Navigation